(European Society of Cardiology) Inclisiran lowers low-density lipoprotein (LDL; 'bad') cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late-breaking results from the ORION 1 trial presented today in a Hot Line LBCT Session at ESC Congress.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2vCMohS
No comments:
Post a Comment